Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 17/20 | 0.70 |
| ▸ | PLK3 | Q9H4B4 | 16/20 | 0.70 |
| ▸ | NEK2 | P51955 | 4/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.70 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.70 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.70 |
| ▸ | PIM1 | P11309 | 2/20 | 0.70 |
| ▸ | KDR | P35968 | 2/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973679 | 0.91 | PLK1 (0.72) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4398808 | 0.90 | PLK1 (0.69) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL2986655 | 0.90 | PLK1 (0.85) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4397911 | 0.90 | PLK1 (0.56) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4397580 | 0.90 | PLK1 (0.56) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4413881 | 0.89 | PLK1 (0.56) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4402962 | 0.89 | PLK1 (0.69) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4397830 | 0.88 | PLK1 (0.73) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4397738 | 0.88 | PLK1 (0.58) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4402879 | 0.88 | PLK1 (0.55) | PLK1PLK3NEK2PIK3CDNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786127-B2 | Benzimidazole thiophene compounds | Glaxo SmithKline LLC (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1937671-B1 | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595330-B2 | Benzimidazole thiophene compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | CHEUNG MUI | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214567-A1 | Benzimidazole Thiophene Compounds | ABCB1, ABCG2, CYP3A5 | PLK1 344/4885PLK3 934/4885NEK2 2296/4885 |
| US-20070270437-A1 | Benzimidazole Thiophene Compounds | ABCB1, CYP3A5, ABCG2 | PLK1 458/4885PLK3 1235/4885NEK2 2703/4885 |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | PLK1 1718/4885PLK3 2097/4885NEK2 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.